Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type ...
Atavistik Bio’s $120 million Series B financing bolsters its push to advance first-in-class, allosteric small-molecule therapies for HHT and MPNs, leveraging its AMPS platform to selectively target ...
Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) ...
Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, ...
Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...
Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...
Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...
Company to present at 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15Label expansion submissions for BESREMi® (ropeginterferon alfa-2b-njft) filed with FDABURLINGTON, ...
One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs ...
8don MSN
BRAF gene mutation leads to different therapeutic responses in melanoma and colorectal cancer
A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the ...
New research indicates that a long-maligned menopausal treatment is safer than previously thought, showing that it doesn’t increase breast cancer risk in women with inherited mutations in the BRCA1 or ...
Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback